320 related articles for article (PubMed ID: 16401247)
21. Long-lasting effects of a new memory self-efficacy training for stroke patients: a randomized controlled trial.
Aben L; Heijenbrok-Kal MH; Ponds RW; Busschbach JJ; Ribbers GM
Neurorehabil Neural Repair; 2014; 28(3):199-206. PubMed ID: 24300949
[TBL] [Abstract][Full Text] [Related]
22. Psychosocial problems associated with depression at 18 months poststroke.
De Ryck A; Fransen E; Brouns R; Geurden M; Peij D; Mariën P; De Deyn PP; Engelborghs S
Int J Geriatr Psychiatry; 2014 Feb; 29(2):144-52. PubMed ID: 23625635
[TBL] [Abstract][Full Text] [Related]
23. Poststroke fatigue: risk factors and its effect on functional status and health-related quality of life.
Chen YK; Qu JF; Xiao WM; Li WY; Weng HY; Li W; Liu YL; Luo GP; Fang XW; Ungvari GS; Xiang YT
Int J Stroke; 2015 Jun; 10(4):506-12. PubMed ID: 25472471
[TBL] [Abstract][Full Text] [Related]
24. Relationships among pain, depressed mood, and global status in fibromyalgia patients: post hoc analyses of a randomized, placebo-controlled trial of milnacipran.
Arnold LM; Palmer RH; Gendreau RM; Chen W
Psychosomatics; 2012; 53(4):371-9. PubMed ID: 22677218
[TBL] [Abstract][Full Text] [Related]
25. Potential predictors for health-related quality of life in stroke patients undergoing inpatient rehabilitation.
Chen CM; Tsai CC; Chung CY; Chen CL; Wu KP; Chen HC
Health Qual Life Outcomes; 2015 Aug; 13():118. PubMed ID: 26243294
[TBL] [Abstract][Full Text] [Related]
26. Controlled comparison of two different doses of milnacipran in major depressive outpatients.
Kanemoto K; Matsubara M; Yamashita K; Tarao Y; Inada E; Sekine T
Int Clin Psychopharmacol; 2004 Nov; 19(6):343-6. PubMed ID: 15486520
[TBL] [Abstract][Full Text] [Related]
27. Depression and Functional Status Among African American Stroke Survivors in Inpatient Rehabilitation.
Harris GM; Collins-McNeil J; Yang Q; Nguyen VQ; Hirsch MA; Rhoads CF; Guerrier T; Thomas JG; Pugh TM; Hamm D; Pereira C; Prvu Bettger J
J Stroke Cerebrovasc Dis; 2017 Jan; 26(1):116-124. PubMed ID: 27720524
[TBL] [Abstract][Full Text] [Related]
28. Post-stroke depression among stroke survivors attending two hospitals in Kampala Uganda.
Gyagenda JO; Ddumba E; Odokonyero R; Kaddumukasa M; Sajatovic M; Smyth K; Katabira E
Afr Health Sci; 2015 Dec; 15(4):1220-31. PubMed ID: 26958024
[TBL] [Abstract][Full Text] [Related]
29. Anxiety and depressive symptoms after stroke in 9 rehabilitation centers.
Masskulpan P; Riewthong K; Dajpratham P; Kuptniratsaikul V
J Med Assoc Thai; 2008 Oct; 91(10):1595-602. PubMed ID: 18972905
[TBL] [Abstract][Full Text] [Related]
30. Subtle problems in activities of daily living after a transient ischemic attack or an apparently fully recovered non-disabling stroke.
Verbraak ME; Hoeksma AF; Lindeboom R; Kwa VI
J Stroke Cerebrovasc Dis; 2012 Feb; 21(2):124-30. PubMed ID: 21115361
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Cognitive Rehabilitation Therapy on Poststroke Depression among Survivors of First Stroke Attack in Ibadan, Nigeria.
Olukolade O; Osinowo HO
Behav Neurol; 2017; 2017():4058124. PubMed ID: 28720980
[TBL] [Abstract][Full Text] [Related]
32. Quality of life after stroke in a rehabilitation setting.
Giaquinto S; Giachetti I; Spiridigliozzi C; Nolfe G
Clin Exp Hypertens; 2010; 32(7):426-30. PubMed ID: 20874223
[TBL] [Abstract][Full Text] [Related]
33. Post-stroke depression and expressed emotion.
Rashid N; Clarke C; Rogish M
Brain Inj; 2013; 27(2):223-38. PubMed ID: 23384219
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcome in stroke survivors after discharge from a convalescent rehabilitation ward.
Mutai H; Furukawa T; Araki K; Misawa K; Hanihara T
Psychiatry Clin Neurosci; 2013 Sep; 67(6):434-40. PubMed ID: 23941061
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of milnacipran on the depressive state in patients with Alzheimer's disease.
Mizukami K; Tanaka Y; Asada T
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1342-6. PubMed ID: 16603301
[TBL] [Abstract][Full Text] [Related]
36. Plasma levels of milnacipran and its effectiveness for the treatment of chronic pain in the orofacial region.
Kimura H; Yoshida K; Ito M; Tokura T; Nagashima W; Kurita K; Ozaki N
Hum Psychopharmacol; 2012 May; 27(3):322-8. PubMed ID: 22585592
[TBL] [Abstract][Full Text] [Related]
37. An evaluation of efficacy and safety of reboxetine in elderly patients affected by "retarded" post-stroke depression. A random, placebo-controlled study.
Rampello L; Alvano A; Chiechio S; Raffaele R; Vecchio I; Malaguarnera M
Arch Gerontol Geriatr; 2005; 40(3):275-85. PubMed ID: 15814161
[TBL] [Abstract][Full Text] [Related]
38. The influence of early depressive symptoms, social support and decreasing self-efficacy on depression 6 months post-stroke.
Volz M; Möbus J; Letsch C; Werheid K
J Affect Disord; 2016 Dec; 206():252-255. PubMed ID: 27513631
[TBL] [Abstract][Full Text] [Related]
39. Prevention of recurrent depressive episodes with milnacipran: consequences on quality of life.
Rouillon F; Berdeaux G; Bisserbe JC; Warner B; Mesbah M; Smadja C; Chwalow J
J Affect Disord; 2000 Jun; 58(3):171-80. PubMed ID: 10802126
[TBL] [Abstract][Full Text] [Related]
40. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine.
Yoshida K; Higuchi H; Kamata M; Takahashi H; Inoue K; Suzuki T; Itoh K; Ozaki N
J Psychopharmacol; 2007 Aug; 21(6):650-6. PubMed ID: 17092970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
